About
Antibody Therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
6,090
By Phase
PHASE3: 3PHASE2: 2
By Status
RECRUITING: 2ACTIVE_NOT_RECRUITING: 2TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT05712200Lead Sponsor
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
PHASE3Recruiting
1,900 participants
Started: Dec 27, 2022 · Completed: Oct 31, 2026
NCT05171075Lead Sponsor
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
PHASE3Recruiting
1,020 participants
Started: Sep 27, 2022 · Completed: Feb 28, 2027
NCT05421533Lead Sponsor
Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
N/ATerminated
705 participants
Started: Sep 14, 2022 · Completed: Sep 30, 2024
NCT05171049Lead Sponsor
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
PHASE3Active, not recruiting
1,150 participants
Started: May 5, 2022 · Completed: Feb 28, 2027
NCT04755283Lead Sponsor
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
PHASE2Active, not recruiting
1,287 participants
Started: Feb 2, 2021 · Completed: Dec 29, 2028
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...